Skip to main content
. 2020 Jan 18;21(2):636. doi: 10.3390/ijms21020636

Figure 7.

Figure 7

HVEM (14–39) peptide blocks BTLA/HVEM binding. 293T cells expressing human BTLA were incubated with peptides (5 mg/mL) prior to labeling with HVEM-Fc and AF647-conjugated anti-human IgG antibody. The blocking capacity of the HVEM (14–39) peptide was first compared to (A) a scrambled (Ac-SECGRCEAPEKTKSLCVTPEPVGCYG-NH2) peptide or (B) to variant peptides (Table S2). The graph shows the geometric fluorescence intensity (GMFI). * p < 0.05, ** p < 0.01, *** p < 0.001 and **** p < 0.0001 following one-way ANOVA and Dunn’s post-test, compared to the HVEM-Fc condition in A and HVEM-Fc or native peptide in B.